{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T23:02:50Z","timestamp":1781650970477,"version":"3.54.5"},"reference-count":18,"publisher":"MDPI AG","issue":"22","license":[{"start":{"date-parts":[[2023,11,9]],"date-time":"2023-11-09T00:00:00Z","timestamp":1699488000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Fujita Health University"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Naldemedine is structurally designed to prevent passage across the blood\u2013brain barrier (BBB), resulting in the attenuation of opioid-induced constipation without interfering with the analgesic effects of opioids. However, the influence of brain metastasis (BM), as one indicator of BBB disruption, on the analgesic effects of opioids in patients treated with naldemedine remains unclear. To examine whether the analgesic effects of opioids following naldemedine treatment are lower in patients with BM than in those without BM, we surveyed inpatients with lung and breast cancers treated with naldemedine at Fujita Health University Hospital between April 2017 and March 2022. Changes in the numeric rating scale (NRS) scores, morphine milligram equivalents (MMEs), and the number of rescues were assessed as analgesia-related outcomes during the first 7 days of naldemedine treatment in patients with or without BM, matched by the propensity score. In total, 172 patients were enrolled. After propensity-score matching, 30 patients with BM and 60 patients without BM were included in the analysis. Changes in NRS scores, MMEs, and the number of rescues did not differ between patients with and without BM. In the linear mixed-effects model, the coefficient of interaction between patients with or without BM and the days for each outcome was not statistically significant. BM does not influence the analgesic effect of opioids in patients with lung and breast cancers treated with naldemedine. Naldemedine may be useful for treating BM.<\/jats:p>","DOI":"10.3390\/jcm12226997","type":"journal-article","created":{"date-parts":[[2023,11,9]],"date-time":"2023-11-09T03:42:40Z","timestamp":1699501360000},"page":"6997","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Influence of Brain Metastasis on Analgesia-Related Outcomes in Patients with Lung and Breast Cancers Treated with Naldemedine: A Propensity Score-Matched Analysis"],"prefix":"10.3390","volume":"12","author":[{"given":"Aya","family":"Hanamoto","sequence":"first","affiliation":[{"name":"College of Pharmacy, Kinjo Gakuin University, Nagoya 463-8521, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2889-9586","authenticated-orcid":false,"given":"Takenao","family":"Koseki","sequence":"additional","affiliation":[{"name":"Department of Pharmacotherapeutics and Informatics, Fujita Health University School of Medicine, Toyoake 470-1192, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayaka","family":"Utsunomiya","sequence":"additional","affiliation":[{"name":"Department of Pharmacotherapeutics and Informatics, Fujita Health University School of Medicine, Toyoake 470-1192, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuma","family":"Ishihara","sequence":"additional","affiliation":[{"name":"Innovative and Clinical Research Promotion Center, Gifu University Hospital, Gifu 501-1194, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takao","family":"Tobe","sequence":"additional","affiliation":[{"name":"Department of Pharmacotherapeutics and Informatics, Fujita Health University School of Medicine, Toyoake 470-1192, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Kondo","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Fujita Health University School of Medicine, Toyoake 470-1192, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Kijima","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, Fujita Health University School of Medicine, Toyoake 470-1192, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7837-565X","authenticated-orcid":false,"given":"Hiroshi","family":"Matsuoka","sequence":"additional","affiliation":[{"name":"Department of Surgery, Fujita Health University School of Medicine, Toyoake 470-1192, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Mizuno","sequence":"additional","affiliation":[{"name":"Department of Pharmacotherapeutics and Informatics, Fujita Health University School of Medicine, Toyoake 470-1192, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Hayashi","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Kinjo Gakuin University, Nagoya 463-8521, Japan"},{"name":"Department of Pharmacotherapeutics and Informatics, Fujita Health University School of Medicine, Toyoake 470-1192, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeki","family":"Yamada","sequence":"additional","affiliation":[{"name":"Department of Pharmacotherapeutics and Informatics, Fujita Health University School of Medicine, Toyoake 470-1192, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,11,9]]},"reference":[{"key":"ref_1","first-page":"1837","article-title":"Opioid-Induced Constipation and Bowel Dysfunction: A Clinical Guideline","volume":"18","author":"Bassotti","year":"2017","journal-title":"Pain Med."},{"key":"ref_2","first-page":"425","article-title":"Opioid therapy for chronic noncancer pain: Practice guidelines for initiation and maintenance of therapy","volume":"71","author":"Coluzzi","year":"2005","journal-title":"Minerva Anestesiol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.2147\/JPR.S243435","article-title":"Naldemedine: A New Option for OIBD","volume":"13","author":"Coluzzi","year":"2020","journal-title":"J. Pain Res."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.dmpk.2018.12.002","article-title":"Minimal contribution of P-gp on the low brain distribution of naldemedine, a peripherally acting \u03bc-opioid receptor antagonist","volume":"34","author":"Watari","year":"2019","journal-title":"Drug Metab. Pharmacokinet."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41568-019-0205-x","article-title":"The blood-brain barrier and blood-tumour barrier in brain tumours and metastases","volume":"20","author":"Arvanitis","year":"2020","journal-title":"Nat. Rev. Cancer"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"989","DOI":"10.4155\/tde.15.48","article-title":"Promising approaches to circumvent the blood-brain barrier: Progress, pitfalls and clinical prospects in brain cancer","volume":"6","author":"Papademetriou","year":"2015","journal-title":"Ther. Deliv."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"239","DOI":"10.3389\/fonc.2018.00239","article-title":"Beyond the Blood:Brain Barrier: The Importance of Central Nervous System (CNS) Pharmacokinetics for the Treatment of CNS Tumors, Including Diffuse Intrinsic Pontine Glioma","volume":"8","author":"Warren","year":"2018","journal-title":"Front. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e13563","DOI":"10.1111\/nmo.13563","article-title":"Pharmacologic effects of naldemedine, a peripherally acting \u03bc-opioid receptor antagonist, in in vitro and in vivo models of opioid-induced constipation","volume":"31","author":"Kanemasa","year":"2019","journal-title":"Neurogastroenterol. Motil."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"3859","DOI":"10.1200\/JCO.2017.73.0853","article-title":"Randomized Phase III and Extension Studies of Naldemedine in Patients with Opioid-Induced Constipation and Cancer","volume":"35","author":"Katakami","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S2468-1253(17)30105-X","article-title":"Naldemedine versus placebo for opioid-induced constipation (COMPOSE-1 and COMPOSE-2): Two multicentre, phase 3, double-blind, randomised, parallel-group trials","volume":"2","author":"Hale","year":"2017","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1097\/j.pain.0000000000001174","article-title":"Long-term use of naldemedine in the treatment of opioid-induced constipation in patients with chronic noncancer pain: A randomized, double-blind, placebo-controlled phase 3 study","volume":"159","author":"Webster","year":"2018","journal-title":"Pain"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e000527","DOI":"10.1136\/esmoopen-2019-000527","article-title":"Safety and efficacy of naldemedine in cancer patients with opioid-induced constipation: A pooled, subgroup analysis of two randomised controlled studies","volume":"4","author":"Osaka","year":"2019","journal-title":"ESMO Open"},{"key":"ref_13","first-page":"4290","article-title":"Towards updated understanding of brain metastasis","volume":"12","author":"Wang","year":"2022","journal-title":"Am. J. Cancer Res."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Archie, S.R., Al Shoyaib, A., and Cucullo, L. (2021). Blood-Brain Barrier Dysfunction in CNS Disorders and Putative Therapeutic Targets: An Overview. Pharmaceutics, 13.","DOI":"10.3390\/pharmaceutics13111779"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1177\/0897190017732263","article-title":"Peripherally Acting \u03bc-Opioid Receptor Antagonists for the Treatment of Opioid-Related Side Effects: Mechanism of Action and Clinical Implications","volume":"31","author":"Streicher","year":"2018","journal-title":"J. Pharm. Pract."},{"key":"ref_16","first-page":"e16201","article-title":"Efficacy and Safety of Peripherally Acting \u03bc-Opioid Receptor Antagonist (PAMORAs) for the Management of Patients with Opioid-Induced Constipation: A Systematic Review","volume":"13","author":"Rekatsina","year":"2021","journal-title":"Cureus"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"5209","DOI":"10.1007\/s00520-021-06070-7","article-title":"The influence of brain metastases on the central nervous system effects of methylnaltrexone: A post hoc analysis of 3 randomized, double-blind studies","volume":"29","author":"Brenner","year":"2021","journal-title":"Support. Care Cancer"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"4734","DOI":"10.7150\/thno.69682","article-title":"Challenges and opportunities to penetrate the blood-brain barrier for brain cancer therapy","volume":"12","author":"Upton","year":"2022","journal-title":"Theranostics"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/22\/6997\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:19:44Z","timestamp":1760131184000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/22\/6997"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,9]]},"references-count":18,"journal-issue":{"issue":"22","published-online":{"date-parts":[[2023,11]]}},"alternative-id":["jcm12226997"],"URL":"https:\/\/doi.org\/10.3390\/jcm12226997","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,9]]}}}